CILP and hyperphosphatemia: CILP1 can inhibit the response of insulin-like growth factor 1 (IGF-1) in chondrocytes, thereby impacting cell growth and repair, indirectly promoting hyperphosphatemia in aging and osteoarthritis, and increasing expression in early osteoarthritis patients [29,30,31,32,33].